The proteins expre~scd by mutated oncogenes are in essence cancer-specific pro· teins and thus potential cancer-specific antigens. Gene translocation often result! in the expression of chimeric fusion proteins with unique amino acids at the joining region segment that are also cancer-specific proteins. T cells recognize small peptides and are, therefore, particularly adept at discriminating between single amino acid substitutions. Oncogenic proteins that result from somatic DNA mutations or gene translocation and have aberrant amino acid sequences offer an opportunity to elicit specific T cell responses.
The appropriateness of any cancer-specific protein to serve as a T cell target depends upon whether the protein has the proper molecular configuration or 'motif' to bind in the cleft of class I or class II MHC molecules; whether the resultant peptide/MHC molecule complex is present at the cell surface of the target cell or antigen presenting cell (APe) in a concentration high enough La stimulate the specific T cell receptor: and, finaHy, whether the peptide/MHC mol ecule complex is within the T cell receptor repertoire of the particular nominated individuals_ A potentia] disadvantage of directing T cell immunity against mu tated portions of oncogenic proteins is that not every patient will be able to respond to a single epitope on a given protein.
Recent studies have shown that immune responses to both mutated and over expressed oncogenic proteins can occur in patients with malignancy or can be elicited in animal models. (Cheever et al. 1990 994a, Fenton et al. 199J, Fossum et a1. 1994b , Gambaco rt i-Passerini et al. 1993 , Gedde-Dahl et al. I992b, Ioannides et al. 1993a ,b, Peace et al. 1991 , Peoples et a!. 1995 , Yanuck et a!. 1993 . The observation that immunity to oncogenic proteins is present in some patients with malignancy begs the issue of whether such immune responses play any role in slowing cancer progression and whether boosting of immune responses can offer any therapeutic benefit. Much has been written over the years on the role of immunity to cancer. However, most current theories of host-tumor interactions were formulated without firm evi dence as to the molecular identity of the antigens that are recognized or have the potential to be recognized. Few studies have evaluated immunity to known and defined antigens and explored the role immunity plays in disease progression, Such studies are now possible, The current article will review data from our lab oratory evaluating immunity to three prototype oncogenic proteins, HER-2/neu, ras and bcr-abL The potentia] advantages and the pitfalls of this approach will be presented.
IMMUNITY OF HER-2JNEU PROTEIN

Background
HER-2/neu has been studied as a prototype of a specific category of tumor anti gen -oncogenic proteins that are overexpressed as a result of gene amplification.
[rvIMUNITY TO ONCOGENIC PROTE [NS 35 HER-2!neu is a self protein, expressed by some normal tissues. but often overex pressed by cancer cells. One ploy used to identify human tumor antigens has been to characterize the antigens 00 autologous tumors thal are n:cognized by autochthonous T cells. The antigens identified by such studies have thus f:.n been shown to be largely 'self' proteins expressed on normal as well as malignant cells (Houghton 1994 . Pardol! 1994 . These 'self' antigens have included proteins expressed during fetal development but only on rare adult tissues (i.e.. MAGE I). as well as proteins reluted to the differentiated function of the involved tissue of malignant origin (i.e., tyrosinase. melanoma A and PM ELI 7). These finding have increased the importance to tumor immunology of the study of immuoilY to self antigens.
HER·::!/neu. a member of the epidermal growth factor receptor family. is pre sumed to function as a growth factor roceptor (Coussens ct a!. 1985) . This trans membrane protein is related to EGFR and consists of a cysteine~rich extracellular domain which functions in ligand binding and a cytoplasmic domain with kinase activity. Monoclonal antibodies have been generated to the HER-21neu protein which are capable of inducing either stimulatory ·or inhibitory signals on the receptor (Harwerth et al. 1992 , Lupu et al. 1992 . In humans. the HER-2/ncu protein is expressed during fetal development. In adults, the protein is weakly detectable by immunohistochemical staining in the epithelial cells of many normal tissues (Press et al. 1990 ). !n normal cells the HER-2/neu gene is present as a single copy (KaUioniemi et al. 1992) . Amplification of the HER-21neu gene andl or overexpression of the associated protein has been identified in many hUI11:an malignancies.
Cancers in which HER~21neu gene amplification and resultant protein overex pression occur include carcinoma of the breast, ovary, uterus, stomach, and aden ocarcinoma of the lung (Bercbuck et al. 1990 , Kern et aL 1990 , Slamon et a1. 1989 , Yonemura et a!. 1991 . In breast cancer, the HER·2/neu protein is overexpressed in the malignant tissue of 20-40% of invasive ductal carcinoma patients (Allred et al. 1992a) . In ductal carcinoma in situ (DCIS ), a much higher percentage of cancers overexpress the HER-2/neu oncogene, approaching 60-80% (Allred et at 1992a) . HER-2/neu protein overexpression correlates with a signifi cantly worse clinical outcome in most subsets of breast cancer patients (Slamon et al. 1987) . The influence of HER-2/neu overexpression in the outcome of other cancers has not been as well studied.
HER-2/neu has been considered as a potential target for immunotherapy, but it had been assumed that individuals would be immunologically tolerant to this non-mutated self protein. However, we have shown that some breast cancer pa~ tients have pre-existing T cell and antibody immunity to the HER-21neu protein (Disis et al. 1994a ). This suggests that tolerance to HER-2/neu has been overcome in some individuals by' virtue of the overexpresslon of HER-2/neu on autologous cancer cells. Studies examining methods to prospectively circumvent tolerance to rat neu protein (89'1" homologous to human HER-21neu protein) in rats hav, confirmed that rats fail to respond to immunization with whole rat neu protein presumably due to immunologic tolerance. By marked contrast. immunization 0 rats to selected rat neu derived peptides elicits T cell and antibody immunity te rat neu peptides and proteins. The existence of immunity to HER-~/neu in pa· tients with breast cancer and the demonstrated ability to elicit immunity to neL in rats without inducing observable autoimmune toxicity gives impetus to pro· ceeding with human HER-2/neu vaccine and T cell therapy trials.
HER-2/neu human antibody responses
In initial studies to evaluate for the presence of antibody immunity, twenty pre menopausal breast cancer patients were evaluated. These v,:ere participants in the Women's Interview Study Health (WISH) program, an epidemiological study evaluating risk factors for breast cancer recurrence and death conducted through the Fred Hutchinson Cancer Research Center. All stages of invasive breast cancer were included. Detection of serum HER-2Jneu antibodies was done by Western blotting. A very high number of patients, i.e. II of 20 (55%). demonstrated e:<:ist ent HER-2ineu antibody responses. To compare the presence of HER-2/neu anti bodies in a normal population, serum samples were collected from 55 female and 55 male normal blood donors at the Puget Sound Blood Center. In normal fe males, 3 of 55 (5%) had antibodies to HER2/neu. In normal males, 2 of 55 (4%) had antibodies.
In a confirmatory study of premenopausal breast cancer patients from the University of Washington clinics, antibodies to HER-2/neu were identified in II of 25 (44%) individuals. Recombinant proteins representing the intracellular domain (ICD) and extracellular domain (ECD) of the HER-2/neu protein were used to perform epitope mapping. Antibody responses were detected to whole protein and to both the ICD and the ECD (Fig. 1) . Responses varied between patients with some patients responding to either the lCD or the ECD and some re sponding to both.
It is not surprising that antibody to the ICD exists. Presumably, the ICD is normally sequestered from the immune system and becomes exposed only during cancer formation or progression. Antibodies directed against the reD presumably have little access to that portion of the protein and therefore have little function. Given that HER-21neu is a functioning growth factor receptor, antibody to tbe ECD may playa more profound role. Murine monoclonal antibodies to HER-2J neu can have either antagonistic or agonistic function. Autochthonous antibody could have the same spectrum of function and could thereby theoretically have beneficial or detrimental effects in breast cancer patients. The function of existent serum antibody is being evaluated. Figure 1 , Breast cancer patients have antibody responses to both the extra-and intracellular domains of the HER-21neu protein. Purified HER-21neu protein (p 185), recombinant ECD and recombinant lCD were resolved on a 7.5% acrylamide gel (Pharmacia Phast). The proteins were transferred to nitrocellulose. Sera from a breast can~r patient with a HER 2Jneu overexpressing tumor was used as primary antibody in a Western blot analysis at a dilution of 1:500 in PBSI1%BSAlI%NP--40. Goat anti-human HRP was used as the second step antibody at a dilution of 1:5000. The blot was developed using a chemilumenescent reaction (Amersham ECL). This patient had antibodies that responded to both domains. breast cancer patients and is positively correlated with HER-2/neu overexpres sion. In the first 35 sera samples analyzed from breast cancer patients with known HER-1Ineu positive tumors, 46% had antibodies directed against the protein. Given tne small number of patients, nO conclusions can yet be drawn as to the relationship between the site of antibody recognition and clinical parameters. Interestingly, some patients whose tumors did not overexpress the protein also had HER-21neu specific antibodies. Antibody immunity found in some patients with HER-21neu negative breast carcinomas begs tbe question of whether HER 21neu antigen-negative tumor variants evolve through immunoselection. Screening studies of over 200 patients with breast cancer, whose HER~21neu status was unknown, revealed an overall positive antibody response in 13% of patients (Fig.   2 ).
The clinical and biologic nature of antibody immunity to HER-21neu needs to be studied further with the goal of understanding how to harness this antibody • response for therapeutic advantage. Issues that remain to be elucidated include: (1) whether detection of existent antibody immunity to HER-2Jneu bas any diag nostic or prognostic significance; (2) to what extent the presence of antibodies correlates with stage of disease, survival, and tumor overexpression of HER-2J neu; (3) whether the presence of antibodies correlates with the presence of circu lating ECD protein in the serum. The EeD is often found circulating in the sera of breast cancer patients and have been proposed as a tumor marker (Hayes et al. 1993 , Katb et a!. 1993 . Accurate assessment of circulating ECD might require concurrent measurement of antibody to the ECD as well as ECD; (4) (Allred el al. 1992a ). Thus, overexpression of HER-2/ncu appears to be associated with malignant transformation and early neoplasia. but not benign proliferative diseases of the breast. If HER-2/neu anti body immunity is detectable at the early non-invasive DCIS stage of breast can cer-progression then screening assays for antibodies could potentially be used in early detection of breast cancer. It is possible, however, that immune recognition of the overexpressed HER-2/neu protein often does not occur in the early stages of breast cancer when the tumor mass and amount of antigen is small. We have detected antibodies to HER-2/neu in patients with both early stage and advanced stage disease but no patients have been followed longitudinally to determine the kinetics of onset of immunity or the evolution of immunity over time. It is un known whether HER-21neu negative invasive ductal breast cancer arises from HER-2/neu positive DCIS and whether HER-2Jneu inununity plays any role in iromunoselection of progressing HER-2!neu negative cancers.
HER-2/neu human helper T cell responses
The HER-21neu specific antibodies detected were IgG. Immunoglobulin class switch from IgM to IgG requires T cell help, usually provided by cognate recog nition, i.e. helper T cells and antibodies recognize epitopes 00 the same molecule. Helper T cell function requires recognition of epitopes presented by class I1 MHC molecules. Soluble proteins are classically processed in the class II MHC pathway. HER-2Jneu protein is a transmembrane protein present at the cell surface. In vitro, the ECD can be detected in culture media of rapidlY growing HER-2/neu positive breast cancer cell lines (Alper et al. 1990 , Zabrecky et al. 1991 . In vivo, the ECD can often be found circulating in the sera of patients with breast cancer (Leitzel et al. 1992 , Mori et at 1990 . Therefore, HER-2Jneu protein is available to APC for processing in the class II pathway.
Stugies have confirmed that CD4+ T cells reactive to HER-2Jneu proteins and peptides can be detected in the peripheral blood of some patients with HER-2Jneu positive breast cancer in levels consistent with a primed response. Initial studies examined proliferative T ceil responses to whole HER-2Jneu protein partially purified from a human breast cancer cell line and examined responses to selected synthetic peptides constructed according to the natural sequence of the protein.
The peptides were selected by use of a computer protein sequence analysis pack age named TSites (Feller & Cruz 1991) . Two searching algorithms were used. The first was the AMPHI algorithm (Feller & Cruz 1991 , Margalit et al. 1987 for identifying motifs according to alpha-helical periodicity and amphipathicity. The second was the Rothbard and Taylor algorithm for identifying motifs according to charge and polarity patterns (Rothbard & Taylor 1988) . Although peptides that bind to class II MHC molecules are now known not to necessarily form alpha-helical orientations, each of the searching algorithms has empirically been successful in identifying a substantial proportion of helper T cell epitopes in oth proteins (Bisset & Fierz 1993 , Ioannidc$ & Whiteside 1993 , Kutubuddin et , 1993 , Roscoe et al. 1994 ). The HER-2/neu peptides studied were those prediclt by both algorithms.
The constructed peptides were each 15-18 amino acids in length. The optim. peptide length for class II MHC binding depends upon the particular MHC rno ecule. The size was chosen arbitrarily, but with the thought that shorter peptidt would be less likely to contain whole epitopes and that longer peptides would t more likely to contain tolerogenic or otherwise inhibitory epiwpes. In a prelim nary evaluation of peripheral blood lymphocytes from 7 breast cancer patient with known HER-2/neu positive tumors, T cell proliferative responses to whot protein and to the synthetic pep tides were identified in 3 patients. The levels a responses were consistent with pre-ex.istent immunity. A significant response wa defined as a stimulation index (S.L) of greater than 2.0. Patients demonstratel different patterns of response (Fig. 3) . The patient studied in the most detai (Disis et al. \994b ) showed a substantial primed response to two of the HER-2 neu peptides as well as to the whole protein. Thus, immunity to protein wa: evident and immunodominant epitopes were identified. Another patient wa~ shown to respond to several of the peptides, but not to the protein, CD4+ helperl inducer T cell responses were detected to epitopes located in both the leD and the ECD. The final patient had a significant response to the protein, but none oj the peptide epitopes tested. Four of the patients did not have any response to the protein or pep tides, but these patients also did not respond to tetanus toxoid, a common recall antigen. None of 10 normals tested in a similar fashion had evi dence of a proliferative response greater than 1.1 to either the HER-2/neu protein or peptides.
Patients with advanced malignancy often develop immunoincompetence and a general inability to respond to standard recall antigens. We have not yet detected T cell responses to HER-2fneu in patients not responding to tetanus toxoid. Pro liferative responses have been evaluated in an additional 35 breast cancer patients in whom the HER-2/neu tumor status was unknown. Results revealed low level proliferative responses in 5 of 35 individuals. Low level responses were defined as an S.l. of greater than 1.5 and less than 2.0 in response to one or more of the peptides.
HER-2/neu human CTL responses
HER-2Ioeu protein is available to helper T cells in the extracellular environment. HER-2/neu is also available in the class I MHC processing pathway for targeting by CTL. In general, detection of T cell responses in viErO implies prior priming has occurred in vivo. Others have detected CTL s~ific for HER-21neu in patients with HER-21neu positive cancers (Fisk et al. 1994 , Peoples et al. 1995 . c..
Antlgen Figure 3 . CD4+ T cells reactive to the HER-2/neu protein and peptides can be detected in high frequency from some patients with HER-2Jneu positive breast cancer. All 3 breast cancer patients depicted were premenopausal women whose tumors overexpressed the HER 21neu protein. A proliferation assay was performed using purified PBMC as the responding cells. Each experimental group was done in a 24 well replicate. 2x 10 5 PBMClweJl was incubated with no antigen, tetanus toxoid (5 ,ug/ml). pl8S (5 ,ltg/m!), or 50 ,ltg/ml of HER 21neu derived peptide. After 4 days the wells were pulsed with I pO of JH-TdR for 6-8 hours and counted_ The data represents the stimulation index of each experimental group which is the mean of the experimental wells divided by the mean of the wells which con tained no amigen. A stlmulacion index greater than 2 is considered to be indicative of a • primed respOnse.
that the most effective therapeutic anticancer immune responses would utilize a arms of the immune system. The demonstration that HER-2/neu specific CTl a~ well as antibody and helper T cell responses. can be derived from cancer P< tients increases the likelihood that HER-2Jneu can be successfully targeted by . cell vaccines and T cell therapy.
Our own studies have focused on eliciting HER-l/neu specific CTL by primar immunization in ~'ilro. It is difficult and rare to generate CTL in I'itro from un primed populations, especially with human -T cells. Studies to elicit CD8 of-CTI -have been greatly facilitated by the determination that CTL recognize short pep tides bound in the groove of class I MHC molecules and that peptides bmdin~ to particular class I MHC molecules share discernible amino acid sequence mOlif: (Falk et al. 1991) . The identification of peptides with a precise amino acid se quence for binding in the groove of class I MHC molecules has allowed priming with exogenous peptides. (DeBruijn et aL 1991) Exogenous peptides bind to only small numbers of empty class I MHC molecules, but the total number of peptidel MHC molecules containing the designated peptides is relatively high, which allows more effective stimulation and priming of peptide.specific T cells (Carbone et al. 1988 ).
To elicit CTL specific for HER-2Jneu, synthetic peptides were constructed identical to HER-2/neu protein segments with amino acid motifs similar to the published motif for HLA-A2.1 binding peptides. Two different peptides capable of binding to HLA-A2.1 were used to repeatedly stimulate peripheral blood lymphocytes from norma! individuals homozygous for HLA-A2 (Disis et aL 1994b) . CTL were generated that could lyse autologous B cells incubated with the immunizing peptide (Fig. 4) .
The central issue for developing HER-2Jneu·specific CTL is whether or not the HER2Jneu protein is processed and available in the class I MHC antigen pro cessing pathway for lysis by CTL. To determine whether HER-2fneu peptide specific T cell lines could lyse targets endogenously synthesizing antigen, a breast cancer cell line, SKBR3, was transfected to express HLA-A2.1. One of the two HER-21neu peptide specific CTL lines was shown to mediate low level specific lysis of the HER-21neu HLA·A2.1 positive breast cancer line (Fig. 4) . The im munizing peptide was derived from the rCD. Peptide specific CTL recognizing a peptide derived from the EeD, did not lyse the HER-21neu breast cancer cells. The demonstration that HER-2Jneu peptide specific CTL can lyse HER-2fneu breast cancer cells substantiates the studies of others and validates that HER-l/ neu is endogenously processed in the class I MHC processing pathway (Fisk et al. 1994 , Peoples et al. 1995 .
One of the major problems for eliciting tumor-specific CTL, is a lack of knowl edge concerning what peptides are present in the cleft of class I MHC molecules on the tumor cells. The process of primary in vitro immunization, if adequately developed, would provide a means to functionally determine which peptide/MHC complexes were present. Unfortunately, the current process of in vifro priming i~ cumbersome, requiring mUltiple restimulations, and is difficult in that priming is nOt detected in the majority of experiments in our hands using current conditions.
HE R-2/neu peptide vaccinlts can effectively imllluni;e {(lIs
The realisation that patients with HER-2/neu positive cancer can recognize HER 2/neu protein begs the issue as to whether immunity can be prospccti~ely induced and augmented to the extent necessary to treat the malignancy. HER-2/neu is a self protein and the methods to generate immune responses to self tumor associ ated antigens have not been well elucidated. Our initial attempts to induce im munity to self proteins as tumor antigens have focused on this particular 'sen" oncoprotein for the following reasons: (I) The detection of existent immune re sponse to HER-2/neu in some patients assures that tolerance to HER-2/neu can be circumvented in some circumstances; (2) HER-2/neu contains both intracellu lar and -extracellular domains and studies of existent immunity show that HER 21neu is available to both the class I and class (I MHC antigen processing path ways and thus is a potential target for attack by both CD8+ CTL and CD4+
helper/inducer T cells; (3) The existent responses observed are not associated with any obvious autoimmune toxicity. The protein is present in higher concentration on malignant cells (Allred et a1. 1992b ) which means that any immune response elicited and boosted might selectively destroy malignant tissue and not induce autoimmune toxicity against normal tissues expressing low threshold amounts of the protein; (4) The protein is large, 1,260 amino acids, and should contain epi topes capable of binding to most, if not all, dass I and class II MHC molecules and thus should be potentially recognizable by all patients; and finally, (5) HER 2/neu overexpression is associated with aggressive disease. If treatment results in the selection of antigen-negative variants, the resultant cel1s may be less aggressive and the treatment might provide benefit in terms of less aggressive malignancy, even without cure. -We are currently testing a peptide-based vaccine in a rat model prior to initi ating a vaccine trial in patients with breast cancer. The goal of the rat experiments has been to identify HER-2/neu based vaccine formulations that can be used in humans and that are capable of eliciting a high degree of immunity. Other investi gators had failed in attempts to immunize to rat neu protein which is highly homologous to human HER-21neu protein (Bernards et al. 1987) . In those studies rats were injected with a recombinant vaccinia virus vector expressing the extra _cellular domain of rat neu. Although mice immunized with the same vectors developed vigorous immune responses to rat neu, when rats were immuniz.ed they did not develop detectable antibody or DTH responses to the protein. This was an expected result, since the rat neu protein is foreign in mice but self in rats. We have confirmed that rats are tolerant to rat neu protein. In those experiments -I immunization of rats to whole rat neu protein in complete Freund's adjuvant (CFA) failed to elicit immunity.
The ploy used. which worked for circumventing tolerance to whole protein, was to immunize to pcptides rather than whole protein (Disis et al. 1995) . One theory of tolerance to self differentiates responses to dominant and subdominant epitopes (Sercarz et a!. 1993) . During responses to foreign proteins, immunity is elicited to only the dominant epitopes and the subdominant epitopes are ignored. for self proteins, T ceJls capable of recognizing dominant epitopes are eliminated in the thymus or in the periphery, but the subdominant epitopes are 'ignored'. Immunization to truncated proteins or peptides not containing the dominant epi topes elicits T cell immunity to these subdominant epitopes.
A rat model was used to test a HER-21neu peptide based vaccine as rat neu pro tein is 89% homologous to human HER-2/neu protein and has a similar distribution and level of expression. Synthetic peptides identical to the natural sequence of rat neu protein were constructed so that immunization protocols would assess immun ity to self protein as opposed to foreign protein. Rats were immunized with groups of peptides derived from the rCD or the ECD. Rats in both vaccination groups de veloped substantial CD4+ T cell immunity and 19G antibody immunity to neu pep tides and protein. Epitope analysis showed that particular peptides in the vaccine elicited the dominant B cell responses, but also demonstrated 'determinant spread ing'. Antibodies recognized not only the immunizing peptides, but also epitopes in the other domain (Disis et a1. 1995) . Presumably, responses elicited by immuniz ation to either leD or ECD peptides facilitated autologous priming to other epi topes. One conceivable mechanism is that the initial peptide-specific antibodies elicited concentrated autologous protein into APC to levels necessary to prime to other epitopes. Determinant spreading was particularly evident in animals immun ized v.ilh lCD pep tides. A more detailed examination of the dominant epitopes rec ognized following determinant spreading might identify portions of the molecule that would be most effective in vaccine formulations.
Importantly, the antibodies elicited were immune to and capable of immuno precipitating both rat neu and human HER-21neu protein. Using peptide epitopes that were homologous between rat neu and human HER-21neu resulted in re sponses specific for both the rat and human neu proteins. The elicitation of re sponses specific for human HER-21neu protein provides strong evidence that pep tide-based vaccines containing these epitopes would be capable of eliciting a simi lar immune response in humans.
The CD4+ T cell proliferative responses elicited by immunization with the • ICD or the ECD peptides were specific for the immunizing peptides and the peptide-specific T cells could respond to the whole protein. contain an immunogenic epitope. More than one peptide would increase the likeli hood that the vaccine would contain an immunogenic peptide. However. as the number of peptides was increased, the likelihood of including a peptide capable of competitively inhibiting binding of the potentially immunogenic peptides [0 class II MHC molecules would increase. In some rats the stimulation index to groups of peptides was less than the response to selected individual peptides. showing that some form of inhibition, blocking, or suppression did occur. Immu nization to single peptides or different groups of peptides might gi\'e substantially different results. Determination as to which peptides can engender protein-speci fic responses is important, since inclusion of peptitles not engendering protein specific responses in a vaccine formulation would lessen the antitumor effective ness of the vaccine.
In choosing to separately test vaccines containing groups of leO and ECD peptides. our assumption had been that T cell responses to ICD and ECD pep tides might be different. The ICD is more likely to be sequestered from the im mune system and therefore less likely to elicit a tolerizing response. By contrast, the fCD would be more likely to elicit a tolerizing response. In transgenic animal models the level of tolerance to self proteins is related to the level of protein expression. Experimental results showed that both the [CD and the ECD peplides could induce T cell responses. The T cell responses to the ICD peptides appeared to be greater than the responses to the ECD, but only a limited set of peptides was evaluated. Other peptides might yield difIerent results. Thus, no principle has been established. A wider range of peptides needs to be examined to be able to generalize the conclusions.
These results of the rat vaccine studies are extremely encouraging for proceed ing with human vaccine trials. Rat peptides, rather than foreign peptide, were used. Thus, the principle that peptide-based vaccines can be used to circwment tolerance to HER-2Jneu was validated. The rat peptides used were highly homo logous to the human HER-2/neu sequence and the antibodies generated were specific for both rat and human protein. Thus, it can be expected that the same groups of peptides are likely to elicit similar antibody and T cell responses in humans. Whether peptide immunization can lead to therapeutic benefit can only be answered by clinical trials in humans.
Induction of HER-2Inf!U specific immunity in humans by treatment with bispecific antibody specific for HER-21neu and CD16.
Many investigators have recognized the potential role of the HER-2Ineu protein' as a cancer~associated antigen for targeting immunotherapy. Louis Weiner at the Fox Chase Cancer Center in Philadelphia has initiated a Phase I clinical trial using a bispecific monoclonal antibody designated 2B I. 2B 1, developed by David B. Ring at Chirow Corp.. is directed against the extracelhilar domain of HER-2/ IMMUNITY TO ONCOGENIC PRafEINS oeu on cancer cells and the Fcgm receptor (CD 16) on NK cells and macrophages (Weiner ct al. 1993) . En vi/fa 281 can activate such effector cells and mediate lysIs of H ER-2/neu positive cancer cells. Bispecific antibody directed against tumor antigen and Fc receptors might also facilitate the uptake of antigen into amig~n presenting cells via Fc receptor endocytosis, thereby facilitating the presentation of antigen for immune recognition.
\Vorking in collaboration with Drs, Ring and Weiner we have analyzed serum samples from patients treated with the 2B 1 antibody on a dose escalation trial for the possible development of humoral immunity to the HER-2Jneu protein (Gralow et at 1995) , Patients with H ER-2fneu positive breast, ovarian. prosta te and colon cancer were treated in this study. The majority developed HAMA and several developed anti-idiotype antibodies against the HER-2/neu binding region of 2B I. The new and provocative finding was that treatment with 281 elicited human antibodies to HER-2/neu in several patients. HER-2Jneu antibody im munity was confirmed by immunoprecipitation of the 185 kD HER-2/nell mol ecule with patient serum (at a time point following clearance of 28! antibody). Antibodies generated recognized both intracellular and extracellular regions of the HER-2/neu molecule, The antibodies were primarily IgG at day 30, Immuno globulin class switching from IgM to IgG implies the existence of HER-2/neu specific helper T cells, Immune responses to HER-2/neu generated by the 28 I antibody were present long past the time of antibody administration, All re sponding patients continued to have detectable antibody at greater than 100 days post 2B I antibody treatment. There is every expectation that the ongoing immune responses elicited will be as effective or more effective in cancer therapy than the originally infused antibody. Further studies will be required to determine whether the elicitation of immunity results in therapeutic benefit and to define the circum stances in which peptide vs. bispecific antibody vaccines are effective.
IMMUNITY TO RAS PRafEINS
Background
Ras protein has been studied by our group as a prototype of an oncogenic protein that is a result of a somatic DNA point mutation. Ras poiot mutations result in the expression of proteins with single amino acid substitution and aberrant pro tein function, Ras protein was chosen for study because ras mutations are com mon in human malignancy and the common mutations are limited in number and location in the molecule. Importantly, the common mutations present in human malignancy are also commonly observed in murine malignancies, Therefore, the principles developed in animal models should be extrapolatable to humans.
Somatic mutations of ras oncogenes occur in approximately 20% of all human cancers including 90% of pancreatic adenocarcinomas. 60% of follicular carci nomas of the thyroid, 50% of colon adenocarcinomas and 40% of myeloid leuke mias (Almoguera et al. 1988 , Bas 1989 , Bas et al. 1987 . Three ras genes have been defined in the human and the murine genomes, H-ras, K-ras. and N-ras (Stavnezer et al. 1983) . These genes encode a highly conserved group of 2lkO proteins, denoted as p2l ras. 'Activation' of ras occurs by point mutation in the nucleic acid sequence, most commonly at codons 12 or 61. which results in the expression of p21 protein with a corresponding single amino acid substitutions. The activating amino acid substitutions impair intriosic GTPase activity of the ras protein and generate constitutively activated signaling complexes with trans forming activity (Der et a!. 1985 , Seeburg et al. 1984 .
Ras proteins has been defined as tumor antigens in two ways. First, immunity to ras can be elicited in animal models by immunization to ras peptides and protein. A tumor antigen may be defined in several ways. Second, existent immun ity to ras has been observed in patients with cancers normally associated with ras mutations. This section will review our work on both issues.
Murine ras specific helper T cell responses
In initial experiments to evaluate the potential immunogenicity of ras proteins, mice were immunized to synthetic ras peplides Identical to the mutated region. The use of certain mouse strain/ras peptide combinations was shown to elicit CD4+ Class II MHC restricted T cells immune to the immunizing ras peptide (peace et aL 1991). The T cells that were peptide specific did not respond to . homologous ras peptides containing either the native amino acid sequence or alternative amino acid substitutions. The ability of any cancer specific protein to serve as a tumor antigen for CD4+ T cells in any particular host depends upon whether the targeted segment of the protein has the proper molecular configur ation to be presented by host class II MHC molecules and whether the resultant peptide/MHC complex is within the host T cell repertoire. One disadvantage of directing T cell immunity against the mutated portion of oncogenic proteins is that only a subset of patients will be able to respond to any particular single epitope on a given protein. We have not made an exhaustive study of responses to ras peptides in a wide variety of mouse strains. However, in studies immunizing several mouse strains to peptides representing the commonest ras mutations all ras peptides tested were immunogenic in some mouse strains, but no single ras peptide was immunogenic in all mouse strains.
A critical issue is whether peptide specific T cells elicited by immunization to peptides can respond to ras protein containing the same substitution. Peptide specific T cells need not necessarily respond to the parental protein containing the peptide. For recognition by CD4+ T cells, proteins must be internalized, degraded and presented by class II MHC molecules on APe. Peptide epitopes can be destroyed during processing and alternative peptide epitopes can dominate presentation. Results of studies examining responses in a variety of mouse strains
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[0 peptide and protein showed that some. but not all ras peptide specific helper T cells could respond to intact ras protein containing the same mutation (Peace et aJ. 1993 ).
lvIurine ras :,pecijic CTL responses
In animal models, both CD8+ and CD4+ T cell subsets alone are capabl~ of eradicating established tumor (Greenberg 1986 . Greenberg et at. 1985 . but both subsets collaborate in most normal immune responses. and optimal T cell therapy requires both SUbsets. Ras protein is not considered to be a secreted protein. but normal ras protein can be readily detected in bodily fluids under a variety of circumstances (Niman et at. 1985) , and mutated ras has been detected in the extracellular tumor environment (Ng et al. 1989 ). Thus. the mutated product might be available in the external cell environment at sites of tumor deposition to be processed and presented by autologous APC expressing class II MHC antigens. Additionally, ras protein is synthesized within tumor cells and exists in the cytosol and therefore is likely to also be available to the class I MHC processing pathway. Studies have shown that ras specific CTL can be elicited in defined circumstances (Peace et a1. 1994) . However, since the conditions necessary for peptide presen tation to CTL by the class I MHC antigen processing pathway are even more stringent than for class II MHC presentation, it is uncertain as to how commonly the responses will be able to be elicited.
Our own studies (Peace et al. 1994 ) examined CTL responses to the mutated segment of ras protein containing an activating substitution at residue-61 in B6 mice. The amino acid sequence of peptides containing that substitution were con sistent with the published binding motif for B6 class I MHC molecules (H-2b). To evaluate peptide binding to B6 class I MHC molewles RMA-S, a mutant B6 leukemia line which expresses unstable 'empty' class I molecules, was used to assess the ability of ras peptides to bind to and stabilize class I MHC molecules. Pep tides corresponding to the mutated segment of the p21 ras protein enhanced the surface expression of Kb on RMA-S. Incubation of B6 spleen cells with some, but not all, of the stabilizing ras peptides induced CTL specific for the immuniz ing ras peptides. Long-term cultured CD8+ T cell lines established from in vi/ro sensitized spleen cells retained peptide specific cytolytic activity and were able to lyse tumor cells that endogenously express the corresponding p21 ras protein.
The extent to which mutant ras peptides are capable of binding to other murine or human class I MHC molecules is an open experimental question.
Human ras specific antibody responses
The observation that p21 ras protein can be immunogenic in mice increases the likelihood that primed T and B cell responses might be present in patients with 50 CHEEVER ET AL.
ras-positive malignancies and begs the issue as to whether detection of immune responses to p21 ras can bl: used to indicate the presence of small foci of cancer ill vivo. Normally p21 ras is affixed to the inner aspect of the cell membrane. howc'ver. substantial amounts of p2\ ras are released into the sera and bodily fluids of tumor-bearing patients. It is possible that individuals bearing tumors which express aberrant p21 ras can develop speciRc antibodies to the altered ras protein. If present. the detection of human antibodies to mutant p21 ras proteins might be used as a surrogate marker for the presence of tumors expressing mu tated ras proteins.
Our studies examined sera from patients with pancreas and colon cancer for the presence of antibody to ras protein with an EUSA (Takahashi et al. 1995) . A panel of purified p21 ras proteins with. several known single amino acid substi tutions was generated by prokaryotic ~xpression of a mutated synthetic H-ras genes. Antibody to ras was commonly detected in patient sera. In a study exam ining sera from 160 patients with colon cancer and 60 normal volunteers ras reactive antibodies were detected in 32% of patients, but only 3% of normals (Takahashi et al. 1995) . The sera responses to purified ras protein in ELISA have been confirmed by Western analysis of 2-dimensional gels. The greater incidence of antibody in cancer patients provides strong evidence that immunization to the protein occurred as a result of the malignancy.
Although ras p2l protein is activated by point mutation, epitope mapping studies showed that the antibody detected was largely to the wild-type protein and not the mutated, protein. The common mutations in colon cancer occur at codon 12 near the amino terminus. The majority of the antibody detected is reactive with epitopes n~ar the carboxyl. terminus. Although antibody was not specific for mutant ras protein, assays for ras specific antibody responses may provide a highly sensitive method to identify individuals who have been exposed to mutated p21 ras protein and may provide an early indication of incipient or occult malignancies undetectable by conventional methods. The issue of whether the elicitation of a detectable antibody response to ras p21 protein in cancer patients correlates '-'lith important patient characteristics or clinical parameters is being evaluated. molecule (Gedde-Dahl et al. 1992a . Jung & Schluesener 1991 . Further more. T cells specifically recognizing mutated ras pep tides have been isolated from patients with follicular thyroid carcinoma and colorectal cancer (Fossum et at. 1994a ,b. Geddc-Dahl et at. I992b, 1993 .
Human ras specific helper T cell responses
We have ex.tended these studies by examining whether ras peptide-specific CD4+ T cells can be detected in patients with pancreas and colon cancer and furthermore whether ras peptide-specific T cells com recognize ras protein. (Qin et a!. 1995) Peripheral blood mononuclear cells were tested for ability to prolifer ate in response to normal and mutant ras peptidcs and proteins. Normal wild type ras protein contains Gly at amino acid position 12 (denoted GI2). Studies focused on the aspartic acid substitution {denoted D12l, as the commonest muta tion. T cell responses were defined as a stimulation index (S. r.) of >2.0. Res ul ts of preliminary studies showed that 7 of 16 pancreas cancer patients (44%) re sponded to D 12 ras peptide. D 12 ras protein was available for study in only the last 4 patients. Three of-the 4 patients responded to D 12 ras peptide and also showed a su bstantial response to D 12 ras p2 I protein (S.ls. 12. 8 and 24). The other I responded to neither. Specificity was validated by examining responses to alternate ras peptides and proteins. T cell responses to 012 ras peptides were detected in only 2 of 25 (8%) colon cancer patients. The results show that T cell immunity to the mutated segment of ras protein is present in some patients with gastrointestinal cancer. Whether the immunity correlates with the presence of activated ras protein with the same mutation and with clinical outcome will be evaluated. These studies validate that mutant ras protein sequences are within the realm of the human T cell repertoire. Whether immunization can elicit substantial responses and provide beneficial immunity is unknown, but an important issue.
IMMUNITY TO BCR-ABL PROTEIN
Bcr-abl specific helper T cell responses
Both class I and class II T cell responses directed against the mutated segment of p21 ras protein can be elicited to defined mutations in particular mouse strains. Similar studies have been performed to evaluate immunity to the joining region segment of p2l 0 bcr-abl protein. The hallmark of chronic myelogenous leukemia is the translocation of the human c-abl proto-oncogene from chromosome 9 to the specific breakpoint cluster (bcr) region on chromosome 22 (Canaani et al. 1991) . This t(9;22) (q34;q11) translocation is expressed in more than 95% of pa tients with chronic myelogenous leukemia (CML) and in approximately 10% of children and 25% of adults with acute lymphocytic leukemia (ALL) (Canaani et -a!. 1991) . The translocation of the c-abl proto-oncogene on chromosome 9 to the breakpoint cluster region (bcr) on chromosome 22 is exceedingly consistent and usually forms one of two new fusion genes in CML. The t(9;22) translocation results in the formation of a bcr-abl fusion gene that encodes at 210 kD chimeric protein with abnormal tyrosine kinase activity. The ber-abl protein can stimulate the growth of hematopoietic progenitor cells and is essential for the pathogenesis of CMl. The proteins encoded by the c-abl and bcr genes are expressed by nor mal cells and thus presumably are not appropriate targets for T cell auack. How ever, the segment of protein encoded by the joining region of the ber-abl tran script is composed of a uniq ue sequence of amino aeids which are expressed only by malignant cells. Thus, the joining region segment of bcr-abI protein is a leuke mia-specific protein, and a potential target for T cell therapy.
Bcr-abl proteins are appealing candidate targets for immunotherapy for several reasons. First, bcr-abl protein is an antigen shared by many individuals. Second. ber-abl protein is intimately associated with malignant transformation as well as maintenance of the malignant phenotype (Szczylik et al. 1991 , van-Denderen et at. 1989 , van-der-Plas et al. 1989 , Young & Witte 1988 . CML is by all evidence a monoclonal expansion of a single aberrant pleuripotent stem cell (Fialkow et aJ. 1977) . Although controversial (Fialkow et al. 1977 , Lisker et a!. 1980 , it is likely that p210 bcr-abl protein is present in the earliest progenitor malignant cells. Only rarely does Ph-positive CML become Ph-negative. and only rarely does Ph-positive CML lose detectable bcr-abl transcripts during disease pro gression. Thus, antigen negative variants are not a perceived problem. Third, T cells in CML are almost always Ph-negative -at least in chronic phase (CP), and thus, any autochthonous T cell lines to be used for therapy would not be derived from the leukemia clone. Fourth, antigenicity of bcr-abl protein is presumably restricted to the joining region which is expressed only by malignaot cells or 'pre malignant' cells undergoing transformation. Therefore, therapy would be selec tive, minimizing the potential for autoimmune toxicity. Finally, normal bone mar row precursors commonly co-exist with the malignant clone in the bone marrow of CML patients, so that selective destruction of the malignant clone could leave normal hematopoiesis intact.
To evaluate the immunogenicity of ber-abl, mice were vaccinated with synthetic peptides corresponding to the joining region segment ofp21O ber-ab1 protein. Pep tide-specific CD4+ class II MHC-restricted T cells were elicited . The peptide-specific T cells recognized only the chimeric joining region sequence composed of both bcr and e-abl am ino acids. The peptide-specific T cells could rec ognize and respond to p2IO bcr-abl proteins. The response of peptide-specific CD4+ T cells to protein demonstrates that p210 bcr-abl protein can be processed by APe so that the joining region segment is bound to class II MHC molecules in a configuration similar to thac of the immunizing peptide, and in a concentration high enough to stimulate peptide-specific T cells. Thus, p210 bcr-abl protein, as well as p21 ras represent potential tumor-specific antigens related to the transforming event and shared by multiple individuals with malignancies.
Whether bcr-abl protein specific CD4+ T cells can mediate tumor therapy is (Dhut et 31. 1990 ) and is not considered to be a secreted protein, but might be found in the external cellular environment as a result of normal cell death and turnover or as a result of other therapeutic interventions such as cytolytic chemotherapy. We are not aware of any studies that have exam· ined this issue. but bcr-abl protein can be detected in vilro in spent culture super natants, so that presentation by APC is conceivable.
Bcr-abl specific CTL resp0l1.ses
An alternative and conceptually more appealing app~oach to T cell therapy of CML would be to elicit and utilize C08+ CfL with an ability to directly lyse CML cells. However, this approach has not been successful to date. Our primary approach has been to immunize mice in vivo to elicit bcr-abl peptide specific CTL and chen [0 determine whether the peptide specific CTL are capable of lysing murine leukemia cells expressing human bcr-abl protein or human CML cells expressing murine class I MHC. Class I MHC restricted bcr-abl peptide-specific C08+ CTL were elicited by immunization of BALB/c mice with bcr-abl joining region segment peptides . The CTL recognized the combined sequence of bcr-ab! amino acids but neither bcr nor c-abl amino acid sequences alone. Despite substantial specific lytic activity against leukemia cells incubated with exogenous peptide, the CTL failed to lyse syngeneic leukemia cells expressing human bcr-abl protein. Similarly, the peptide-specific CTL fail to lyse human CML cells expressing murine class I MHC antigen, unless the targets were incu bated with exogenous peptide. Not every protein expressed by tumor-related DNA can serve as a T cell target. The peptide fragments of tumor antigens need to be presented to the immune system in the cleft of MHC antigens and be presented in a high concentration. Not every protein and segment of protein will have equal access to the binding cleft of MHC molecules. Some segments of protein may be destroyed by the degradative aspects of antigen processing which occurs via the action of specific proteases. The appropriateness of any particular proto-oncogene product to serve as a T cell target will depend upon whether the peptide/MHC molecule complex is present at the cell surface of the target cell in a concentration high enough to stimulate the specific T cell receptor. Lysis of CML cells by bcr-abl peptide-speci fic CTL is dependent upon whether the peptide-specific CTL have high enough affinity for the bcr-abl peptide/MHC complex and whether the ber-ubl peptide/ ~'lHC complex is present in high enough concentration on the surface of CML cells. No assays exist for either dependency. The only current measure of each is whether target cells are lysed. There is as yet no easy way to determine the proxi· ma te cause of fa ilure when peptide-spt:cifie T cells do not lyse a nllgen-positive target cells. The observation that ber-abl peptide:> can bind to class [ MHC mol ecules and can elicit peptide-specific CTL shows that the generation of CML specific CTL is possible. The failure of CTL to lyse leukemia cells only provides inferential evidence that the bcr-abl joining segment might not be presented by class I MHC molecules. However, the problem may simply be that bcr-abl protein is present in only relatively small amounts which are inadequate for recognition by the CTL utilized. The process of peptide immunization utilizes relatively high concentration of peptide and may yield CTL with an inability to respond to low concentrations of endogenously processed peptide. Development of alternative immunization strategies might allow the generation of more effective eTL.
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